Entrada Therapeutics Q3 net loss narrows 10% to $39.74 million
Bitget2026/11/05 12:23- Entrada Therapeutics’ third-quarter 2026 net loss narrowed 10% to $39.74 million; collaboration revenue fell 44% to $905,000 year-over-year.
- R&D expenses dropped 16% year-over-year to $32.37 million, driven by lower Duchenne preclinical costs and facility-related costs.
- Cash, cash equivalents and marketable securities totaled $193.02 million at September 30, supporting an expected runway into fourth-quarter 2027.
- ELEVATE-44-201 Cohort 1 open-label data are expected by year-end 2026, with Cohort 2 results due in first-quarter 2027.
- ELEVATE-45-201 Cohort 1 met its safety and tolerability objectives; Cohort 2 data are expected in first-half 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Eurozone Sentix Investor Confidence Index slips to 2.4 in November from 2.7 in October
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Crypto prices
More
